Abstract
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Keywords
Immune systemImmune checkpointCancer therapyMedicineCancerTumor microenvironmentImmunologyImmunotherapyInternal medicine
Affiliated Institutions
Related Publications
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
The biologic importance of tumor‐infiltrating lymphocytes
Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...
Immune Regulation of Cancer
Innate and adaptive immune system cells play a major role in regulating the growth of cancer. Although it is commonly thought that an immune response localized to the tumor will...
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...
Understanding the tumor immune microenvironment (TIME) for effective therapy
The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical r...
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 348
- Issue
- 6230
- Pages
- 56-61
- Citations
- 4591
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
4591
OpenAlex
Cite This
Padmanee Sharma,
James P. Allison
(2015).
The future of immune checkpoint therapy.
Science
, 348
(6230)
, 56-61.
https://doi.org/10.1126/science.aaa8172
Identifiers
- DOI
- 10.1126/science.aaa8172